Abstract
Ya z›fl ma Ad re si/Ad dress for Cor res pon den ce: Dr. Meryem Iraz, Bezmialem Vakif Universitesi Tip Fakultesi, Mikrobiyoloji Anabilim Dali, Istanbul, Turkiye Tel.: +90 212 453 17 13 E-posta: meriraz@mynet.com Ge lis ta ri hi/Re cei ved: 13.06.2013 Ka bul ta ri hi/Ac cep ted: 22.08.2013 © Viral Hepatit Dergisi, Ga le nos Ya y› ne vi ta ra f›n dan ba s›l m›fl t›r. / Viral Hepatitis Journal, pub lis hed by Ga le nos Pub lis hing. ABS TRACT Objective: The infections caused by hepatitis B and hepatitis C virus are still remain one of most important health problems for our country. The purpose of this study was to determine the frequency of HBsAg, anti-HBs and anti-HCV positivity in the patients who were admitted to the Research Hospital of the Medical Faculty of Bezmialem Vakif University between November 2011 and May 2013. Materials and Methods: The blood samples were tested for HBsAg, Anti-HBs and anti-HCV by chemiluminescent microparticle immunoassey (CMIA) ( Advia Centaur, Siemens, Almanya) Results: In our laboratuary serologically 53.593 patients are tested for HBsAg, 22.300 patients are tested for Anti-HBs and 39.877 patients are tested for Anti-HCV. In our study 5.5%, 42.2% and 1.3% of the patients are found to be seropositive for HBsAg, Anti-HBs and Anti-HCV respectively. Conclusion: The results detected for hepatitis B and hepatitis C virus seropositivity in our region are comparable to those found in other regions of Turkey. (Viral Hepatitis Journal 2013; 19(3): 106-9)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.